Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

• Type of Material: Article
• Authors: Sagar Lonial, Emory University; Ajay Nooka, Emory University; Praneetha Thulasi, Emory University; Ashraf Z. Badros, University of Maryland; Bennie H. Jeng, University of Maryland; Natalie S. Callander, University of Wisconsin; Heather A. Potter, University of Wisconsin; Douglas Sborov, University of Utah; Brian E. Zaugg, University of Utah; Rakesh Popat, NHS Foundation Trust; Simona Degli Esposti, NHS Foundation Trust; Julie Byrne, GlaxoSmithKline; Joanna Opalinska, GlaxoSmithKline; January Baron, GlaxoSmithKline; Trisha Piontek, GlaxoSmithKline; Ira Gupta, GlaxoSmithKline; Reza Dana, Harvard Medical School; Asim V. Farooq, University of Chicago; Kathryn Colby, New York University; Andrzej Jakubowiak, University of Chicago
• Language: English
• Date: 2021-05-26
• Publisher: SPRINGERNATURE
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2021
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1038/s41408-021-00494-4
• Title of Journal or Parent Work: BLOOD CANCER JOURNAL
• Volume: 11
• Issue: 5
• Start Page: 103
• End Page: 103
• Grant/Funding Information: This study and medical writing support were funded by GlaxoSmithKline (GSK). GSK contributed to study design, implementation, data collection, interpretation, and analysis. Drug linker technology was licensed from Seagen, Inc. (Bothell, WA, USA) and the monoclonal antibody was produced with POTELLIGENT Technology licensed from BioWa (Princeton, NJ, USA). Trademarks are owned by or licensed to the GSK group of companies.
• Keywords: DEPATUXIZUMAB MAFODOTIN; CELL MATURATION ANTIGEN; GSK2857916; Hematology; MONOTHERAPY; DRUG; DREAMM-2; ANTIBODY; Life Sciences & Biomedicine; Science & Technology; OCULAR ADVERSE EVENTS; INHIBITORS; COMBINATION; Oncology
• Research Categories: Physics, Molecular; Health Sciences, Immunology; Biology, Cell; Health Sciences, Oncology

Abstract

Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody–drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit–risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf.